A cute myocardial infarction, secondary to platelet activation and arterial thrombus formation at the site of arteriosclerotic coronary plaque rupture remains the leading cause of death in the Westernized World. [1] [2] [3] In platelets, ATP and ADP are stored in the dense granules and released on activation. ATP and ADP interact with specific receptors on platelets (P2Y 1 and P2Y 12 ) to activate and recruit additional platelets to the site of vascular injury to form a thrombus. [4] [5] [6] Within the vasculature, ATP and ADP levels are regulated by transmembrane nucleotidases that rapidly degrade ATP and ADP to diminish platelet activation and prevent thrombotic events. 7 CD39 (ectonucleoside triphosphate diphosphohydrolase-1) is a 70 to 100 kDa transmembrane protein expressed on the surface of cells that circulate through the blood, lymph, and tissue and the surface of endothelial cells. CD39 hydrolyzes both ATP or ADP directly to AMP. 8, 9 AMP is then hydrolyzed to adenosine by CD73 (ecto-5′-nucleotidase). 10 We have previously demonstrated that increased global expression of the human transgene CD39 (hCD39-Tg) in mice conveys a profound antithrombotic effect. 11, 12 However, the cellular expression pattern necessary to provide this antithrombotic phenotype has not been elucidated. Although previous work suggests that endothelial cell-expressed CD39 and CD73 are key antithrombotic mediators [13] [14] [15] and that hematopoietic expression of CD39 prolongs bleeding time in mice, 12 the contribution of CD39 expression on hematopoietic-derived cells on thrombosis has not been elucidated in depth.
Given the critical role of purine nucleotide signaling in thrombosis and the expression of CD39 on hematopoietic-derived cells, we hypothesized that the level of CD39 activity on bone marrow-derived cells could modulate in vivo occlusive arterial thrombosis. In this report, we demonstrate through bone marrow transplants (BMTs) and targeted depletion of monocytes, that increased CD39 expression on hematopoietic-derived cells, specifically monocytes, conveys resistance to in vivo thrombosis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Increased CD39 Expression Attenuates Platelet Activation
Collagen exposure after vascular injury initiates platelet activation. 16 Whole-blood aggregation was conducted on blood from wild-type (WT) and hCD39-Tg mice to examine the effect of increased CD39 expression on platelet activation by collagen. In response to collagen stimulation of whole blood, platelet aggregation was significantly reduced in hCD39-Tg mice when compared with WT mice ( Figure 1A through 1C ). Similarly, fluorescent activated cell sorting (FACS) analysis showed that after ADP stimulation there was a statistically significant decrease in the binding of fibrinogen to hCD39-Tg platelets compared with WT platelets at 1 and 6 minutes ( Figure 1D ). Also, activation of platelets via thrombin-activating peptide 4 (TRAP-4) resulted in a statistically significant decrease in the percent of hCD39-Tg platelets expressing both activated fibrinogen receptor GPα IIb β 3 and P-selectin when compared with WT platelets ( Figure 1E ). Further quantification of the mean fluorescent intensity (MFI) of both activated fibrinogen receptor GPα IIb β 3 and P-selectin demonstrated a significant decrease in the MFI for both P-selectin and activated fibrinogen receptor GPα IIb β 3 in hCD39-Tg platelets compared with WT platelets (Figure IA through ID in the online-only Data Supplement). Previous work has demonstrated that protease-activated receptor 4 activation is necessary for platelet thrombus propagation. 17 Together, these data demonstrate that increased CD39 expression decreases the activation of platelets in response to collagen, ADP, and TRAP-4.
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Ferric Chloride Dose Effect With Ablation of CD73 and the Time to Arterial Thrombosis
Although CD39 catalyzes the hydrolysis of ATP and ADP to AMP, AMP is hydrolyzed by ecto-5′-nucleotidase (CD73) to adenosine. 18 Previous work has suggested that adenosine inhibits platelet activation. 19, 20 Also, previous work has reported that cd73-null (cd73 −/− ) mice display a reduced time to 7.5% FeCl 3 -induced carotid artery occlusion. 21 To evaluate this mouse model, we first measured the expression of CD73 by FACS and showed that when compared with WT, Ly6C + monocytes isolated from peripheral blood mononuclear cells are indeed null for CD73 expression (Figure 2A and 2B). To measure whether a more rapid time to occlusion occurred in cd73 −/− mice, carotid artery injury was induced by a 5% FeCl 3 solution, which resulted in a quicker time to thrombosis when compared with WT mice ( Figure 2C ). The average time to thrombosis was lower in cd73 −/− mice compared with WT mice (WT: 16.8±2.03 minutes, n=12 versus cd73 −/− : 11.87±1.16 minutes, n=13; P=0.05). However, in response to injury induced by 10% FeCl 3 , there was not a significant difference in the time to thrombosis between WT and cd73 −/− mice ( Figure 3E ; WT: 12.69±2.17 minutes, n=6 versus cd73 −/− : 9.7±1.64 minutes, n=5; P=0.31). These results suggest that the activity of CD73 can modulate the time to arterial thrombosis in response to less severe oxidative injury.
Increased CD39 Expression Does Not Require CD73 Activity to Protect Against Arterial Thrombosis
Our previous pharmacological studies suggested that CD73 activity is required for the antithrombotic phenotype observed in hCD39-Tg mice. 11 Thus, our current finding that CD73 expression is not a critical regulator of arterial thrombosis against 10% FeCl 3 conflicts with this previous work. Therefore, we examined whether CD73 activity is required for the antithrombotic effect in hCD39-Tg mice by using hCD39-Tg mice bred onto a cd73-null background (hCD39-Tg/cd73 −/− ). Representative FACS histograms ( Figure 3A and 3B) and quantification ( Figure 3C and 3D) show the concomitant knockout of CD73 and expression of hCD39 in hCD39-Tg/cd73 −/− mice. Consistent with previous work, 11 hCD39-Tg mice have a prolonged time to thrombosis (120±0.0* minutes; *an end-point of 120 minutes was used; >10× the duration of the time to thrombosis in WT mice) when compared with WT mice (12.6±2.17 minutes, n=5). Unlike previous data using 5% FeCl 3 ( Figure 2C ), a 10% FeCl 3 application did not change the time to thrombosis in cd73 −/− mice (9.7±1.64 minutes, n=5) when compared with WT mice ( Figure 3E) . Surprisingly, in mice overexpressing hCD39, ablation of CD73 did not inhibit the prolongation in the time to thrombosis conveyed by hCD39 overexpression (hCD39-Tg/cd73 −/− : 120±0.0* minutes; *an end-point of 120 minutes was used; Figure 3E ). This finding seemed in conflict with our previously reported study demonstrating that the CD73 inhibitor α-β-methylene-ADP (APCP) nullified the prolongation in the time to thrombosis in hCD39-Tg mice. 11 Therefore, we examined whether treatment of hCD39-Tg/cd73 −/− mice with A B C APCP affected the time to thrombosis. Treatment of hCD39-Tg/cd73 −/− mice with either 1 mg or 2 mg of APCP/kg of body weight resulted in abrogation of the thromboprotective phenotype conveyed by hCD39 expression (time to thrombosis: 1 mg APCP/kg body weight=10.4±3.33 minutes, n=7; 2 mg APCP/kg body weight=5.8±1.89 minutes, n=4; Figure 3E ). These data suggest that at the APCP dosage used here and in previous studies, 11, 22 APCP may modulate arterial thrombosis through off-target effects. Indeed, previous work has demonstrated that in cell extracts, APCP can inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP-1), a related nucleotidase that hydrolyzes ATP or ADP to AMP. 23 In this same study, APCP was found not to inhibit CD39 activity in cell lysates. 23 However, we found that treatment of hCD39-expressing HEK cells with increasing concentrations of APCP demonstrated a decrease in total nucleotidase activity at a concentration of 10 −6 to 1 mmol/L ( Figure IIA and IIB in the online-only Data Supplement), suggesting that APCP may have off-target effects. Altogether, the genetic data demonstrate that CD73 expression is not required for the antithrombotic efficacy provided by increased CD39 expression in vivo and critically, that APCP has an off-target effect that negates the protection conveyed by hCD39 overexpression as evidenced in hCD39-Tg/cd73 −/− mice. With these key determinations, we next focused on understanding the cellular expression of CD39 that conveys resistance to thrombosis in vivo.
Resistance to Arterial Thrombosis Is Transferred by Bone Marrow Transplantation
Global overexpression of hCD39 provides a profound protection against arterial thrombosis 11 ; however, the cellular expression of hCD39 necessary for this vascular phenotype is not known. To examine the contribution of hCD39 expression on hematopoietic-derived cells or endothelial cells, BMTs were conducted between WT and hCD39 mice (Donor Recipient: WTWT, WThCD39-Tg, hCD39-TgWT, and hCD39-TghCD39-Tg). Sixty days after BMTs, complete blood counts (Table) and FACS analyses were performed on whole blood obtained from BMT recipient mice ( Figure 4A and 4B). Comparable levels of leukocytes, red blood cells, and platelets were observed between the groups (Table) . In addition to this, WT levels of endogenous mouse CD39 were not affected by BMT ( Figure IIIA and IIIB in the online-only Data Supplement). FACS analysis confirmed functional BMT engraftment by showing hCD39-expressing bone marrow-derived cells in WT mice transplanted with hCD39 bone marrow and lack of hCD39 expression on bone marrow-derived cells in hCD39 mice transplanted with WT bone marrow ( Figure 4B ). Carotid artery injury was induced by application of 10% FeCl 3 , and the time to thrombosis measured to examine the effect of increased CD39 expression on endothelial cells versus circulating blood cells in BMT recipient mice ( Figure 4C ). FeCl 3 -induced arterial thrombosis in chimeric mice revealed a significant prolongation in the time to thrombosis in recipient mice that received hCD39-Tg bone marrow (hCD39-Tg  WT: 315.7±54.6 minutes and hCD39-Tg  hCD39-Tg: 414.3±61.9 minutes). However, mice that received WT bone marrow did not have a prolonged time to thrombosis (WT  WT: 7.97±0.6 minutes and WT  hCD39: 17.15±6.0 minutes). Together, these data demonstrate that increased expression of CD39 on hematopoietic-derived cells rather than endothelial cells contributes to resistance to arterial thrombosis after vascular injury with 10% FeCl 3 .
Increased Monocyte CD39 Expression Inhibits ADP-Induced Platelet Activation
Given the vast distribution of CD39 expression on the vasculature and hematopoietic-derived cells, 9, 24 we examined the expression of hCD39, murine CD39, murine ENPP-1, and murine CD73 on endothelium and selected immune cell No difference in endogenous CD73 was observed between WT and hCD39-Tg endothelium or monocytes; CD73 was expressed on both. To begin to investigate which cell population contributes to the antithrombotic phenotype observed in hCD39-Tg mice, we initially focused on the monocyte population for several reasons. First, although endothelial cells express increased levels of CD39, the FeCl 3 model generates a strong oxidant injury. 25 CD39 is inactivated by oxidant injury 15 ; therefore, we focused on the effect of CD39 on circulating cells. Given that under basal conditions >90% of circulating monocytes express constitutive CD39 24 and because previous work has demonstrated that monocytes are one of the primary cells recruited to sites of vessel injury, 26, 27 we examined the contribution of monocyte-expressed CD39.
We first asked whether increased numbers of WT monocytes, which express CD39, is sufficient to attenuate platelet activation. To answer this, we added increasing numbers of purified WT monocytes to diluted whole blood isolated from WT mice. Platelets were activated with 20µmol/L ADP, and the expression of activated fibrinogen receptor GPα IIb β 3 was determined by FACS. There was no difference in WT platelet activation with the addition of purified WT monocytes (no monocytes: 1773±43.8 MFI, n=4 versus 10 4 monocytes: 1726±89.9 MFI, n=4, versus 10 5 monocytes: 1583±176.0 MFI, n=4; P>0.05; Figure 5A and 5B).
We then examined whether increased CD39 expression on monocytes attenuates platelet activation. To address this, we performed a similar experiment as outlined in the previous paragraph; however, instead of adding purified WT monocytes, we added purified hCD39-Tg monocytes. Representative histograms from FACS analysis ( Figure 5C ) and quantification of the MFI ( Figure 5D ) show increased activated GPα IIb β 3 integrin on WT platelets after stimulation with 20µmol/L ADP (1224±9.9 MFI, n=4). Additionally, mixing of 10 5 purified hCD39-Tg monocytes to WT whole blood produced a statistically significant decrease (663.5±61.5 MFI, n=4; P<0.001) in the exposure of the activated fibrinogen receptor, GPα IIb β 3 ( Figure 5D ). However, when a smaller number of purified hCD39-Tg monocytes, 10 4 cells, were added to WT blood (1160±92.3 MFI, n=4; P=0.97), there was no statistically significant difference in GPα IIb β 3 . Altogether, these results show that increased expression of CD39 in circulating monocytes can decrease ADP-induced platelet activation.
Monocyte Depletion Abolishes the Antithrombotic Phenotypes of Increased CD39 Expression
Given that increased CD39 expression on monocytes reduced ADP-induced platelet activation ex vivo, we next examined whether increased expression of CD39 on monocytes modulates in vivo thrombus formation. We treated WT and hCD39-Tg mice with control liposomes and clodronate-loaded Figure 6A and 6B). After monocyte depletion, WT and hCD39-Tg mice were subjected to 10% FeCl 3 -induced carotid artery injury, and the time to arterial thrombosis measured ( Figure 6C ). Monocyte depletion reduced the time to thrombosis in hCD39 mice to that observed in both control and clodronate liposome-treated WT mice (hCD39-Tg: control liposome: 120.0±0.0* minutes;
*an end-point of 120 minutes was used; clodronate liposome: 8.0±1.0 minutes; WT: control liposome: 8.62±1.3 minutes; clodronate liposome: 7.81±0.8 minutes). These results demonstrate that increased CD39 on monocytes can attenuate occlusive arterial thrombosis in mice.
Discussion
In this study, we have demonstrated that increased CD39 expression on hematopoietic-derived cells, specifically monocytes, attenuates platelet activation and diminishes occlusive arterial thrombus formation in vivo. Furthermore, using genetic and pharmacological interrogation, we demonstrate that the activity of CD73 is not necessary for the antithrombotic efficacy achieved with increased CD39 expression. Together, these data identify monocyte-expressed CD39 as a key regulator of platelet activation and arterial thrombosis. Nucleotides released from injured or activated cells trigger purinergic receptor activation critical to thrombotic and inflammatory events. These nucleotide signals are extinguished by specific nucloetidases that hydrolyze nucleotides to nucleosides. The main pathway is the hydrolysis of ATP and ADP to AMP by CD39 followed by CD73-mediated hydrolysis of AMP to adenosine. CD73 is expressed on endothelial cells and some leukocytes. [28] [29] [30] It has been reported that mice with a genetic ablation of CD73 have a decrease in the time to carotid arterial thrombosis after FeCl 3 -mediated vascular injury. 21 Furthermore, it has been suggested that addition of a soluble form of CD73 to whole blood reverses ADP-induced platelet aggregation. 31 In the current study, we demonstrated that ablation of CD73 activity had significant but temporally minimal effect on the average time to thrombosis in response to 5% FeCl 3induced carotid thrombosis ( Figure 2E ). However, in response to a more severe injury with 10% FeCl 3 , no difference in the time to thrombosis was observed in CD73-null mice. Our results obtained with 5% FeCl 3 are consistent with data in the literature 21 ; however, the effect of 10% FeCl 3 was found not to be inhibited by the absence of CD73 in the present study. Therefore, we interpret the effect of CD73 on preventing arterial thrombosis as minimal. Most importantly, using genetic models, we found that ablation of CD73 activity did not abrogate the antithrombotic efficacy conveyed by increased expression of hCD39 in mice. This genetic finding was at odds with our previously published work demonstrating that treatment of hCD39-Tg mice with the CD73 antagonist APCP abrogated the protective phenotype observed in hCD39-Tg mice. 11 Our observation that treatment of hCD39-Tg/cd73 −/− mice with the CD73 inhibitor APCP abrogated protection conveyed by hCD39 overexpression, suggesting potential off-target effects of APCP in vivo. This finding contradicts a Figure 6 . Resistance to arterial thrombosis is decreased with clodronate liposome depletion of monocytes in human CD39 transgenic (hCD39-Tg) mice. A through C, Eight-to-12-wk-old wild-type (WT) or hCD39-Tg male mice were treated intravenously with control-loaded liposomes or clodronate-loaded liposomes for 18 h. A, Representative dot plots of peripheral blood mononuclear cells showing the percent Ly6C + (of CD45 + , CD11b + ) monocytes treated with control and clodronate liposomes and (B) quantification of control (WT n=6, hCD39 n=4) and clodronate liposome (WT n=7, hCD39 n=5) treated mice. C, Time to thrombosis after 10% ferric chloride challenge in WT (control liposome n=8, clodronate liposome n=8) and hCD39-Tg (control liposome n=10 and clodronate liposome n=14) mice after treatment. Time to thrombosis was considered to be 120 min. Bars in scatter plots represent the mean±SEM. In (B), the P value was determined by 1-way ANOVA with multiple comparisons using control liposomes as a baseline for LyC6 + monocytes. In (C), the P value was determined by 1-way ANOVA with Tukey correction for multiple comparisons.
recent study examining APCP analogs that reported no inhibition of CD39 activity by APCP when using cell lysates from hCD39-expressing cells. 23 However, on the cell membrane, CD39 forms monomers, dimers, and tetramers that facilitate cooperative activity. 32 Using HEK293 cells expressing human CD39, we observed that APCP treatment resulted in a decrease in CD39 activity in transfected cells ( Figure IIA and IIB in the online-only Data Supplement). Thus, APCP may affect yet unidentified pathways that regulate nucleotide metabolism and contribute to thrombosis. The fact that in mice lacking CD73 expression the CD73 inhibitor APCP abrogates the antithrombotic phenotype conveyed by overexpression of hCD39 demonstrates an off-target effect of APCP in vivo.
The generation of adenosine is limited in the vasculature to the activity of CD73 and circulating alkaline phosphatases. Previous work has suggested that CD73 and tissue nonspecific alkaline phosphates comprise the major AMPhydrolyzing enzymes in plasma. 33 An alternate unexplored explanation is that APCP may inhibit tissue nonspecific alkaline phosphate activity. Thus, in the absence of CD73, as in our cd73 −/− mice, tissue nonspecific alkaline phosphate metabolize CD39-generated AMP and thus still convey protection from thrombosis. However, with APCP treatment of cd73-null mice, the lack of both AMP-hydrolyzing pathways could result in an accumulation of AMP and end-product inhibition of CD39 activity. Alternatively, as mentioned earlier, APCP also inhibits ENPP-1, which metabolizes ATP or ADP to AMP. However, given the relatively low levels of ENPP-1 expression that we have demonstrated on endothelium and monocytes, the relative contribution of ENPP-1 to regulating thrombosis seems low.
Several studies have suggested that endothelial expressed CD39 is responsible for maintaining platelet quiescence under normal physiological conditions. 8, 15, [34] [35] [36] [37] However, with vascular injury, CD39 activity is lost. 15, 38 Furthermore, oxidative stress in endothelial cell injury can decrease CD39 activity. 15, 38, 39 In humans, CD39 expression is lower in culprit lesions in patients with unstable angina compared with those with stable angina and is reduced in coronary atherectomy specimens with thrombus formation. 40 Additionally, postmortem evaluation of patient's samples deceased from acute myocardial infarction exhibit decreased CD39 enzymatic activity in tissue isolated from the coronary artery. 41 Additionally, it has been reported that low levels of circulating CD39 activity are associated with critical limb ischemia in patients with peripheral atherosclerosis compared with patients with claudication. 42 Therefore, CD39 activity or expression at sites of vascular injury or dysfunction has been postulated to be a critical regulator of thrombosis.
Previous studies have shown that increased CD39 expression can have wide regulatory effects in different pathological conditions. For example, increased CD39 expression on either vasculature or blood is sufficient to disrupt hemostasis and prolong bleeding time. 12 Also, increased expression of CD39 can protect kidneys from ischemia-reperfusion injury 43 and ameliorate streptozotocin-induced diabetes mellitus in mice. 44 In addition to this, we have previously reported that hCD39-Tg mice have reduced platelet aggregation, prolonged bleeding times, and a marked resistance to arterial thrombosis. 11 However, these previous studies did not elucidate the cellular requirement of increased CD39 expression to prolong the time to occlusive arterial thrombosis. Here, using complementary approaches of BMTs, ex vivo mixing studies and in vivo monocyte depletion studies, we have demonstrated that increased expression of CD39 on monocytes is capable of attenuating platelet activation and prolonging the time to occlusive arterial thrombosis. This finding is supported by a previous work suggesting that leukocyte-expressed nucleotidase activity may regulate platelet reactivity. 45 First, the platelet aggregatory response to ADP is decreased in whole blood compared with that observed in platelet-rich plasma. 45 Second, patients with leukocytosis have increased leukocyte CD39 expression and reduced ADP-induced platelet aggregation in whole blood. 45, 46 Last, the addition of polymorphonuclear and mononuclear leukocytes to platelet-rich plasma decreased ATP-induced aggregation. 20 However, in this previous work, although it was suggested that nucleotidase activity on leukocytes was responsible for the antiaggregatory results, neither the specific nucleotidases nor the specific leukocyte populations responsible for this effect was identified. Together, these data suggested a role for leukocyte-expressed nucleotidases as a critical mediator in the cross talk that regulates platelet activation and aggregation. In the current study, we demonstrate for the first time that increased CD39 activity on monocytes can inhibit platelet aggregation and reduce the time to occlusive arterial thrombosis.
Previous work has shown that BMTs, where hCD39-Tg mice are used as donors, can lead to decreased levels of cellular reconstitution. 47 This was evidenced by decreased percentage of donor hCD39-Tg cells in liver, spleen, and thymus after BMTs. 47 In addition to this, hCD39-Tg mice show decreased percentages of MHC (major histocompatibility complex)-class II restricted CD4 + T cells and invariant natural killer T cells present in the liver and the spleen. 47 Although CD4 + T cells 48 and invariant natural killer T cells have been linked to atherosclerosis, 49 the effect of these cell types in the acute setting of thrombosis has not been investigated. However, in the current study, we determined that after BMT, recipient mice transplanted with hCD39-Tg bone marrow had reconstituted CD45 + hCD39-expressing leukocytes ( Figure 4A and 4B) . The difference in cellular reconstitution could be because of the difference of BMT timing (42 days 47 versus 60 days in the current study) or the fact that the current study focused solely on circulating blood cells rather than organs responsible for central/ peripheral immunity.
Previous work has shown that CD39 activity can be retained in microparticles derived from platelets, endothelium, and leukocytes. 50 The presence of microparticles has been shown in human plasma, 51 and dysregulation of their activity has been associated with human disorders such as idiopathic pulmonary hypertension. 52 Additional studies are needed to determine whether monocyte-derived microparticles modulate arterial thrombosis in the setting of increased CD39 expression. This avenue of research is of great interest because it would provide novel approaches for therapeutic intervention against arterial thrombosis.
In this study, we chose an updated model of the FeCl 3induced model of arterial thrombosis that was initially developed in rats 53 and later revised for mice. 54 This mouse model has been reviewed extensively 25, 55, 56 and relies on the application of FeCl 3 to the common carotid artery. FeCl 3 -induced thrombosis has been used in numerous reports to study vessel occlusion in response to platelet surface molecules, 57,58 P2Y 12 receptor antagonism, 59 thrombin regulation, 60, 61 cell cycle inhibition, 62 factor Xa inhibition, 63 thrombolysis, 64 and multiple other pathways that can affect vascular function. [65] [66] [67] We chose this model because FeCl 3 -induced thrombi share remarkable features with those observed in humans. For example, FeCl 3 application leads to the formation of platelet-rich thrombi, 54 lipid peroxidation, 68 endothelial cell denudation, 69 and expression of localized adhesion molecules that lead to platelet activation and leukocyte recruitment to the injured artery. 70 Therefore, FeCl 3 -induced model of arterial thrombosis has been an essential tool for the understanding of multiple molecular pathways involved in thrombosis. However, this model is not without critique, and it is important to recognize that the exact mechanism by which FeCl 3 causes arterial damage is an important topic of debate 71 with recent work showing that the primary cell type binding damaged endothelial surfaces might be red blood cells rather than platelets. 72 Regardless of the primary adhering cell, the FeCl 3 -induced model of arterial thrombosis is a model of thrombus propagation. 25, 55, 56 These current explorations regarding the mechanisms involved in FeCl 3 -induced arterial thrombosis not only allow us to make cautioned interpretations about phenotypes observed in the FeCl 3 -treated mouse but also highlight the importance of such a critical mouse model used to investigate human arterial thrombosis.
The relevance to human cardiovascular disease is that single-nucleotide polymorphisms rs10748643 and rs7071836 in the CD39 gene associated with the level of CD39 expression. 73, 74 We have demonstrated that the presence of rs10748643 genotypes associates with secondary cardiovascular events in patients with intracoronary stent placement for coronary artery disease. 75 Whether genetic determinants regulate CD39 expression on human monocytes is the focus of ongoing clinical studies.
In conclusion, increased CD39 expression conveys an antithrombotic phenotype that is independent of CD73 activity. Transfer of bone marrow with increased levels of CD39 is sufficient to transmit the antithrombotic phenotype of hCD39-Tg mice. In addition to this, depletion of monocytes ablates the antithrombotic effect of increased CD39 expression. Together, these data strongly suggest that increased CD39 expression on monocytes can attenuate platelet activation and in vivo thrombosis.
